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Abstract
One of the major players in the pathophysiology of cerebral ischemia is disrupted homeosta-
sis of glutamatergic neurotransmission, resulting in elevated extracellular glutamate (Glu)
concentrations and excitotoxicity-related cell death. In the brain, Glu concentrations are reg-
ulated by Glu transporters, including Glu transporter-1 (GLT-1) and cystine/Glu antiporter
(system xc
-). Modulation of these transporters by administration of ceftriaxone (CEF, 200
mg/kg, i.p.) or N-acetylcysteine (NAC, 150 mg/kg, i.p.) for 5 days before focal cerebral ische-
mia may induce brain tolerance to ischemia by significantly limiting stroke-related damage
and normalizing Glu concentrations. In the present study, focal cerebral ischemia was
induced by 90-minute middle cerebral artery occlusion (MCAO). We compared the effects
of CEF and NAC pretreatment on Glu concentrations in extracellular fluid and cellular-spe-
cific expression of GLT-1 and xCT with the effects of two reference preconditioning meth-
ods, namely, ischemic preconditioning and chemical preconditioning in rats. Both CEF and
NAC significantly reduced Glu levels in the frontal cortex and hippocampus during focal
cerebral ischemia, and this decrease was comparable with the Glu level achieved with the
reference preconditioning strategies. The results of immunofluorescence staining of GLT-1
and xCT on astrocytes, neurons and microglia accounted for the observed changes in extra-
cellular Glu levels to a certain extent. Briefly, after MCAO, the expression of GLT-1 on astro-
cytes decreased, but pretreatment with CEF seemed to prevent this downregulation. In
addition, every intervention used in this study seemed to reduce xCT expression on astro-
cytes and neurons. The results of this study indicate that modulation of Glu transporter
expression may restore Glu homeostasis. Moreover, our results suggest that CEF and NAC
may induce brain tolerance to ischemia by influencing GLT-1 and system xc
- expression lev-
els. These transporters are presumably good targets for the development of novel therapies
for brain ischemia.
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Introduction
Excitotoxicity related to excessive glutamate (Glu) release plays an important role in the patho-
physiology of brain ischemia [1]. Glutamate transporter 1 (GLT-1) and cystine/glutamate anti-
porter (system xc
-) are the principal proteins that cooperate in the active regulation of Glu
extracellular concentrations [2,3]. GLT-1 transports Glu from the extracellular space to astro-
cytes, whereas system xc
- is implicated in the active transport of cystine to the intracellular
space and reverse transport of Glu. Since brain ischemia is accompanied by a massive release
of Glu, the recognition of the role of GLT-1 and system xc
- may to be crucial for understanding
stroke pathophysiology and potential therapies. The glutamatergic system plays also a role in
the development of brain tolerance to ischemia in response to short-lasting ischemia–a phe-
nomenon called ischemic preconditioning (IP). Damaging brain ischemia decreases GLT-1
protein expression [4], whereas IP upregulates GLT-1 expression [5] and reduces ischemia-
induced Glu release [6]. However, the effects of ischemia on system xc
- expression are still
poorly characterized. Previously, we found that the expression of xCT mRNA decreased with
no effect on protein levels 24 hours after focal cerebral ischemia [7], but there are also other
inconsistent reports showing increased neuronal injury, following hypoxic-ischemic insults,
associated with enhanced Glu excitotoxicity via increased function of the xc
- system. This neu-
ronal injury was facilitated by IL-1b. [8]
Pharmacological modulation of GLT-1 by β-lactam antibiotics, including ceftriaxone
(CEF), induces upregulation of GLT-1 expression and shows neuroprotective effects [9]. Intra-
peritoneal (i.p.) administration of CEF for five consecutive days prior to 90-minute middle
cerebral artery occlusion (MCAO) has been shown to significantly reduce infarct volume and
neurological deficits in rats [7,10].
N-acetylcysteine (NAC), a cysteine prodrug necessary for glutathione synthesis, can stimu-
late system xc
- activity [11]. In transient focal cerebral ischemia, NAC administered at the time
of reperfusion significantly reduces infarct volume and levels of proinflammatory cytokines
[12]. Repeated administration of NAC before transient ischemia significantly reduces infarct
volume and expression of xCT protein [7]. System xc- is composed of two distinct subunits,
xCT which is the light chain, catalytic protein, and 4F2hc which is the heavy chain protein,
anchoring the light chain to the cellular membrane [3]. NAC has potent antioxidant proper-
ties, but it may also increase Glu concentration in the synaptic cleft and thus contribute to the
progression of excitotoxicity.
Previously, we showed that CEF and NAC exert neuroprotective properties in the MCAO
model (see Supporting Information figures: S13 Fig) [7]. CEF blunted downregulation of
GLT-1 protein and mRNA, but also xCT mRNA however, not protein after cerebral ischemia
(see Supporting Information figures: S14 and S15 Figs) [7]. NAC reduced the expression of
xCT protein but not mRNA. These results are similar to the effects of two other well-recog-
nized models of preconditioning, IP and chemical preconditioning with 3-nitropropionic acid
(3NP). However, it is unclear, whether above changes evoked by CEF affect Glu level in brain
ischemia. In vitro study reveals, that cells obtained from hippocampal CA1 field of animals pre-
treated with CEF either prior to SHAM-operation or global brain ischemia showed signifi-
cantly increased Glu up-take. These effects were directly associated with GLT-1 activity [13].
Secondly, there is also no direct evidence that NAC reduces Glu levels during the time course
of brain ischemia-reperfusion. This drug has been thought to reverse extracellular Glu eleva-
tions in psychotomimetic-induced models of schizophrenia [14]. Thus, mentioned results
strongly suggest that the observed modulation of the studied Glu transporters, namely GLT-1
and xc- may be associated with changes in Glu levels during the time-course of brain ische-
mia-reperfusion.
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In the current study, we continued to investigate the role of modulation of GLT-1 and xCT
expression levels in the context of extracellular Glu levels in the ischemic brain and the cellular
localization of Glu transporters. The present study is the first report about the fluctuation of
Glu level in the extracellular fluid of the rat brain subjected to brain ischemic preconditioning,
but also after treatment with CEF, NAC and 3NP. Since the mechanism of co-regulation of
GLT-1 and xCT transporters is still poorly understood, the knowledge about the changes of
Glu level in brain injury, neurodegenerative diseases, brain preconditioning is demanded.
Methods
Animals
All experiments were performed on male Wistar rats (280–320 g, Charles Rivers). The animals
were maintained on a normal day-night cycle at 22±2˚C with free access to food and water. All
experimental protocols were in accordance with the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health and were approved by the First Local
Ethical Committee at Jagiellonian University in Krakow (Permit No: 78/2011). All studies
involving animals are reported according to the ARRIVE (Animal Research: Reporting of In
Vivo Experiments) guidelines, including the blinding procedure of animal identities at each
level of the experiment.
Drugs and experimental design
CEF, NAC and 3NP were prepared in saline (the pH of the NAC solution was neutralized with
10% NaOH solution). The animals received one of the following solutions: CEF, NAC (200
mg/kg or 150 mg/kg body weight, respectively) or saline i.p. for five consecutive days. The last
injection was administered 3 days prior to the 90-minute MCAO surgery or sham procedure.
3NP was administered in a single dose (20 mg/kg body weight) 3 days prior to 90-minute
MCAO or sham surgery. The injection volume was 1 μL/g body weight.
The rats were randomly divided into the following ten groups of sixteen animals each:
sham-operated rats receiving saline (SHAM), 90-minute MCAO rats receiving saline (ISCH),
20-minute MCAO 3 days prior to sham surgical procedure (IP), 20-minute MCAO 3 days
prior to 90-minute MCAO (IP+MCAO), 3NP administration 3 days prior to sham surgical
procedure (3NP), 3NP administration 3 days prior to 90-minute MCAO (3NP+MCAO),
sham-operated rats receiving NAC (NAC), 90-minute MCAO rats receiving NAC (NAC
+MCAO), sham-operated rats receiving CEF (CEF), and 90-minute MCAO receiving CEF
(CEF+MCAO). Eight animals from each group were assigned to a microdialysis study, and the
remaining eight rats were sacrificed for immunofluorescence staining.
Implantation of microdialysis probe
Guide cannulas were implanted 24 hours prior to any surgical procedure. The rats were anes-
thetized with a ketamine/xylazine mixture (75 mg/kg ketamine, 5 mg/kg xylazine of body
weight) administered i.p. The animals were stereotaxically implanted with guide cannulas
(MAB 4; AgnTho’s, Stockholm, Sweden) aimed at the frontal cortex [anteroposterior (AP):
-0.48 mm; mediolateral (ML): +2.0 mm; dorsoventral (DV): -1.2 mm] and the hippocampus
(AP: -4.36 mm; ML: +1.8 mm; DV: -2.5 mm) according to the atlas of Paxinos & Watson
(1998). The guide cannulas were affixed to the skulls with dental acrylic cement. Obturators
were placed in the cannulas until the microdialysis probes were inserted.
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Microdialysis procedure
Microdialysis probes were perfused with artificial cerebrospinal fluid (aCSF) (in mM: NaCl
147, KCl 4.0, MgCl2 1.0, CaCl2 2.2, pH 7.4) at a constant flow rate (2 μL/minute) for two hours
prior to collecting the first baseline sample. Next, the obturators were removed from the guide
cannulas, and the microdialysis probes (MAB 4, membrane with a molecular weight 6-kDa
cut-off, 2-mm length, 0.24-mm outer diameter, AgnTho’s AB, Lidingö, Sweden) were inserted
into the guide cannulas. Next, the brain structures of animals dedicated to MCAO surgical
procedures were perfused for 2 hours. After this period, samples were collected every 30 min-
utes as follows: two baseline samples, three samples during MCAO and two samples during
the reperfusion period. All samples were immediately frozen and stored at -80˚C until the
LC-MS assay.
Focal cerebral ischemia model
Middle cerebral artery occlusion was performed according to the method of Longa et al. [15]
to induce transient focal cerebral ischemia. All surgical procedures were carried out under a
stereoscopic microscope (MST 132 Lab 8, PZO Warszawa), and body temperature was main-
tained at a physiological level using a heating blanket (Homeothermic blanket system; Harvard
Apparatus). The effectiveness of MCAO was confirmed using a blood flowmeter (PeriFlux
System 5000; Perimed). Rats were anesthetized with a ketamine/xylazine solution (3/1, v/v,
respectively) administered i.p. The doses of ketamine and xylazine were 75 mg/kg and 5 mg/kg
body weight, respectively. The surgical procedure involved exposure of the left external carotid
artery (ECA), the internal carotid artery (ICA) and the common carotid artery (CCA). All
branches of the ECA were coagulated, and the artery was ligated and cut. The ICA and CCA
were temporarily secured with microvascular clips. A silicone-coated filament (Doccol) was
introduced into the lumen of the ECA and advanced until the blood flow dropped. The
remaining clip on the CCA was removed, and the wound was secured with silk sutures. The
occlusion times were 20 and 90 minutes for IP and MCAO, respectively. After the occlusion
period, the wound was reopened, and the filament was removed to restore the blood flow. The
wound was closed with sutures. The sham operation was carried out as described above, but
the filament was not inserted.
Liquid chromatography
The chromatographic separation was performed on an Agilent HPLC 1100 series system (Agi-
lent, Waldbronn, Germany), which was equipped with a degasser, binary pump, autosampler
and thermostated column compartment. The aCSF samples were separated on a LiChrospher
60 RP-select B column (125 mm x 4.6 mm ID, 5-μm particle size) in combination with an
appropriate guard column (4 mm x 4 mm; 5-μm particle size) (Merck, Germany). All chro-
matographic separation parameters were used according to Jastrzębska et al. [16]. Samples
were prepared by mixing 30 μL of the extracellular fluid with 4 μL of the internal standard
Glu-d5 (25 μg/mL). The standard curve was plotted relating the glutamate concentration of
standards to the peak area ratio of the glutamate to internal standard Glu-d5. The glutamate
standard concentrations used for the preparation of the standard curve were as follows: 0, 25,
50, 100, 250, 500 and 1000 ng/mL of the extracellular fluid. Pairs of ions were monitored in the
assay with the following values of m/z: 148.0/84.1 for Glu, 153.22/89.1 for Glu-d5. Data were
analyzed using Analyst software 1.4 (AB SCIEX, USA). Levels of Glu were calculated using the
calibration standard curves, which were constructed by linear regression analysis of peak area
versus concentration curves.
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Tissue fixation
All rats were subjected to intracardiac 4% paraformaldehyde (PFA) perfusion 24 hours after
the last surgical procedure. First, the animals were deeply anesthetized with ketamine (80 mg/
kg) and xylazine (20 mg/kg). Then, the rats were transcardially perfused with 250 mL NaCl
solution (0.9%; 32˚C) until all remaining blood was removed. Next, the animals were perfused
with 500 mL 4% PFA in 0.1 M phosphate-buffered saline (PBS). After the procedure, the brains
were removed and maintained in the same 4% PFA solution overnight. Then, the brains were
transferred to 0.1% sodium azide solution in 0.1 M PBS and stored until sectioning. Tissues
were cut into coronal 50-μm sections using an automatic Vibratome (Leica VT1200 S) and
stored in antifreezing medium solution (30% glycerol, 30% ethylene glycol in PBS).
Immunohistochemistry—Double staining
All staining procedures, except for antigen retrieval, were conducted in sterile 24-well plates
on a shaker. The sections were washed twice in PBS and transferred to glass vessels filled with
tri sodium citrate buffer solution (pH9), which was used as an antigen retrieval buffer. The
glass containers were closed with caps and moved to a water bath for 30 minutes at 80˚C.
Next, the containers were removed from the water bath and allowed to return to room temper-
ature. The sections were then transferred to 24-well plates and washed twice in 0.2% Tween in
PBS solution (PBST). Nonspecific antibody binding was blocked using 10% donkey normal
serum (DNS) or 10% donkey and goat serum (1:1) (DNS+GNS) solution in PBST, depending
on the combination of secondary antibodies. After a 1-hour incubation at room temperature,
the blocking buffer was removed, and antibodies were added to the appropriate wells (antibod-
ies and working dilutions are listed in Table 1). Results of specificity analysis of anti-xCT pri-
mary antibody are available in the Supplementary Information (S16 Fig). The slices were
double-stained for GLT-1 or xCT together with neuronal marker (MAP2) or astroglial marker
(GFAP) or microglial marker (Iba1). Each mixture of two specific antibodies was dissolved in
an appropriate 2% DNS or DNS+GNS serum in PBST. Then, the 24-well plates were placed in
fridge at 4˚C overnight. The following day, the plates were removed from the fridge and incu-
bated for one hour on shaker at room temperature. Next, the sections were washed twice in
2% DNS or DNS+GNS in PBST, and secondary antibodies dissolved in PBST were added to
the appropriate wells and incubated for 1 hour in the dark at room temperature. Finally, the
sections were washed three times in PBST, transferred to microscopic glass slides, dried,
mounted in Fluoroshield mounting medium (Sigma) and coverslipped. The staining was visu-
alized using a Leica DMIL fluorescence inverted microscope. Images of motor-frontal cortex
and CA1 field of the hippocampus were captured by a digital CCD camera (Leica DFC3000G).
Table 1. The list of specific primary and secondary antibodies as well as sera used in immunofluorescence staining with the appropriate
dilutions.
Primary antibodies Secondary antibodies Serum
Anti-xCT rabbit (ab37185 Abcam) dilution: 1:200 Donkey anti-rabbit TR (ab6800 Abcam) dilution: 1:1000 Donkey normal serum (ab7475 Abcam)
dilution: 10%
Anti-EAAT2 mouse (sc135892 Santa Cruz
Biotechnology) dilution: 1:100
Donkey anti-mouse TR (sc2785 Santa Cruz
Biotechnology) dilution: 1:300
Goat normal serum (50062Z Thermo Fisher
Scientific) dilution: 10%
Anti-GFAP goat (sc6170 Santa Cruz
Biotechnology) dilution: 1:100
Donkey anti-goat FITC (sc2024 Santa Cruz
Biotechnology) dilution: 1:300
Anti-Iba1 goat (ab5076 Abcam) dilution: 1:200 Goat anti-chicken Alexa Fluor 488 (A11039 Thermo
Fisher Scientific) dilution: 1:300
Anti-MAP2 chicken (ab5392 Abcam) dilution:
1:1000
https://doi.org/10.1371/journal.pone.0186243.t001
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Statistical analysis
Microdialysis results were analyzed by 2-way repeated measures ANOVA with Sidak post hoc
test. Each statistical analysis compared four experimental groups: intervention alone, interven-
tion + MCAO, SHAM and MCAO. Data are presented as the mean ± S.E.M. A probability
value of p< 0.05 was considered significant.
Results
Extracellular levels of glutamate
In the MCAO group, a dramatic increase in Glu levels was observed in both the frontal cortex
and hippocampus at 30, 60 and 90 minutes of occlusion. During the first 60 minutes of reper-
fusion, the Glu levels decreased and were similar to those in the MCAO and SHAM groups in
the frontal cortex. In the hippocampus at 30 minutes of reperfusion, significantly increased
Glu concentrations were recorded in the MCAO group (Figs 1A and 2A).
Two-way ANOVA revealed that the level of Glu during ischemia was significantly lower (at
30 minutes after occlusion p< 0.05 at 60 minutes and 90 minutes after occlusion, p< 0.001)
in the frontal cortex of animals pretreated with CEF than that in non-pretreated animals (Fig
1F). A similar reduction was observed in the hippocampus (at 30 minutes and 60 minutes after
occlusion p< 0.001) but not at the end of ischemia, when no significant differences were
recorded (Fig 2F). Glu concentrations at baseline and during reperfusion were similar in both
groups (CEF+MCAO and MCAO) and both brain structures.
As shown by two-way ANOVA, NAC pretreatment significantly decreased Glu concentra-
tion during the entire ischemia period in the frontal cortex (p< 0.001) (Fig 1G), whereas this
effect was observed at only 30 and 60 minutes after occlusion in the hippocampus (p< 0.001)
and not at 90 minutes (Fig 2G). Moreover, in the frontal cortex of NAC-pretreated animals,
the Glu concentration remained significantly lower (p< 0.05) within the first 30 minutes of
reperfusion.
In the IP group, two-way ANOVA showed significantly reduced Glu concentrations in the
frontal cortex and hippocampus at all three occlusion time points (p< 0.001) (Fig 1H). Inter-
estingly, the baseline Glu level was significantly lower (p< 0.05) in the hippocampus, and this
reduction was also observed at the beginning of reperfusion (p< 0.001) (Fig 2H).
Preconditioning with 3NP significantly reduced Glu concentrations in the frontal cortex
during ischemia (p< 0.001), with no influence on the baseline and reperfusion periods (Fig
1I). Whereas in the hippocampus of animals pretreated with 3NP, Glu reduction was observed
not only during occlusion (at 30 and 60 minutes p< 0.001, at 90 minutes p< 0.01) but also at
baseline (p< 0.001) compared with that in the MCAO group. This reduction was also present
within the first 30 minutes of reperfusion (p< 0.01) (Fig 2I).
Immunofluorescence staining of brain slices
Merged images of studied slices showed expression of GLT-1 on astrocytes (GFAP), but there
was no expression of this transporter on neurons (MAP-2) or microglia (Iba1). Expression of
xCT was visible on all studied cells.
Pretreatment with CEF seemed to prevent downregulation of GLT-1 on astrocytes after
90-minute ischemia in both the frontal cortex and hippocampus (Figs 3 & 4). Similar results
were seen in the brains of rats subjected to 90-minute MCAO preceded by IP or 3NP. Similar
to our previously published ELISA results [7] (see S14 Fig), we did not observe notable effects
of NAC treatment on GLT-1 expression in any brain structure. For SHAM groups, see figure
in S1 Fig and figure in S2 Fig.
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GFAP and xCT double staining showed that every intervention used resulted in diminished
xCT expression in astrocytes in the frontal cortex and hippocampus after prolonged ischemia
(figures in S3–S6 Figs).
Only in animals pretreated with CEF, the results of MAP2 staining suggested that neuronal
expression of xCT was reduced in the frontal cortex but not in the hippocampus. In the
remaining groups of animals subjected to ischemia, the coexpression of MAP2/xCT was com-
parable to that of the MCAO group (Figs 5 & 6). SHAM groups are presented in figure in S7
Fig and figure in S8 Fig.
The expression of xCT was found only on microglia of animals pretreated with 3NP 72
hours before ischemia. In the remaining groups subjected to ischemia, the coexpression of
Iba1/xCT was inconspicuous (figures in S9–S12 Figs).
Fig 1. Glu concentration changes in dialysate samples during brain ischemia/reperfusion in the frontal cortex. The level of Glu is expressed
as μg/mL aCSF. Data are presented as the mean ± SEM (n = 8). Two-way repeated measures ANOVA was conducted, followed by Sidak post hoc test
(*p<0.05, **p <0.01, ***p<0.001 compared with ISCH or SHAM). Microdialysates were collected during the following periods: preischemia (-30 to 0
minutes); ischemia (0–90 minutes) and reperfusion (90–150 minutes). (A) MCAO vs SHAM, (B) CEF vs SHAM, (C) NAC vs SHAM (D) IP vs SHAM,
(E) 3NP vs SHAM, (F) CEF + MCAO vs MCAO, (G) NAC + MCAO vs MCAO, (H) IP + MCAO vs MCAO, (I) 3NP + MCAO vs MCAO.
https://doi.org/10.1371/journal.pone.0186243.g001
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Discussion
Excitotoxicity is the first and the most intensively studied molecular mechanism of cerebral
ischemia. This process is based on the massive release of Glu, overstimulation of glutaminergic
receptors with simultaneous failure of reuptake mechanisms. Excessive amount of Glu acti-
vates many intracellular pathways, what inter alia cause increased calcium influx, activation of
protein kinases, generation of reactive oxygen species. Because all these processes are demand-
ing energy, exicitotoxicity results in the ATP depletion, loss of membrane potential, dysfunc-
tion of the respiratory chain and activation of various cell death pathways, including apoptosis
and necrosis. Excitotoxicity of glutamate is a key player in neurodegenerative diseases such as
amyotrophic lateral sclerosis, Azheimer’s disease and Parkinson’s disease. The pathological
role of Glu is also crucial in stroke and traumatic brain injury-induced neurodegeneration
Fig 2. Glu concentration changes in dialysate samples during brain ischemia/reperfusion in the hippocampus. The levels of Glu are
expressed as μg/mL aCSF. Data are presented as the mean ± SEM (n = 8). Two-way repeated measures ANOVA was conducted, followed by Sidak
post hoc test (*p<0.05, **p <0.01, ***p<0.001 compared with ISCH or SHAM). Microdialysates were collected during the following periods:
preischemia (-30 to 0 minutes); ischemia (0–90 minutes) and reperfusion (90–150 minutes). (A) MCAO vs SHAM, (B) CEF vs SHAM, (C) NAC vs
SHAM (D) IP vs SHAM, (E) 3NP vs SHAM, (F) CEF + MCAO vs MCAO, (G) NAC + MCAO vs MCAO, (H) IP + MCAO vs MCAO, (I) 3NP + MCAO vs
MCAO.
https://doi.org/10.1371/journal.pone.0186243.g002
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Fig 3. Expression of GLT-1 on astrocytes within motor-frontal cortex. GLT-1 (Texas Red, red) and GFAP (FITC, green)
double staining of brain sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale bars represent
25 μm, for each group n = 8.
https://doi.org/10.1371/journal.pone.0186243.g003
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Fig 4. Expression of GLT-1 on astrocytes within CA1 field of hippocampus. GLT-1 (Texas Red, red) and GFAP (FITC,
green) double staining of brain sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale bars
represent 25 μm, for each group n = 8.
https://doi.org/10.1371/journal.pone.0186243.g004
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Fig 5. Expression of xCT on neuronal cells within the motor-frontal cortex. xCT (Texas Red, red) and MAP2 (Alexa Fluor
488, green) double staining of brain sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale bars
represent 25 μm, for each group n = 8.
https://doi.org/10.1371/journal.pone.0186243.g005
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Fig 6. Expression of xCT on neuronal cells within the CA1 field of the hippocampus. xCT (Texas Red, red) and MAP2
(Alexa Fluor 488, green) double staining of brain sections of animals subjected to 90-minute MCAO, preceded by
preconditioning. Scale bars represent 25 μm, for each group n = 8.
https://doi.org/10.1371/journal.pone.0186243.g006
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[17]. Numerous clinical trials have focused on the inhibition of glutamate-mediated neurotox-
icity in many various central nervous system diseases including brain ischemia, however with
no success. Brain preconditioning which induce brain tolerance to ischemia brings new hope
for the development of new therapeutic strategies of clinical relevance. The mechanism of this
phenomenon is not fully explained however, it has been shown it involves glutamatergic sys-
tem modulation [18]. The aim of brain preconditioning is to reduce glutamate excitotoxicity,
however still there is no pharmacological approach to induce this phenomenon. Our team is
focused on the search for the pharmacological agents, e.g. CEF or NAC, inducing brain toler-
ance to ischemia (see S13 Fig).
The results of the current study confirmed that 90-minute MCAO caused a significant
increase in the extracellular Glu levels in the frontal cortex and hippocampus [19,20]. This
finding may be associated with reduced expression of GLT-1 after prolonged cerebral ische-
mia. The results of our previous study showed a significant downregulation of GLT-1 in the
frontal cortex and hippocampus at both the mRNA and protein levels following cerebral ische-
mia [7] (see S14 Fig). Similar conclusions were drawn by Zhang et al. [21]. Immunohisto-
chemically, weaker expression of GLT-1 on astrocytes has been shown in the hippocampal
CA1 field of animals subjected to ischemic insult [21].
In the present study, we used two different approaches, namely, IP and 3NP, which are
known methods that can induce brain tolerance to ischemia. IP involves multidirectional
molecular changes, and modulation of the glutamatergic system is one of its most important
elements [22]. For instance, mild activation of the NMDA receptor is involved in the develop-
ment of brain tolerance to ischemia during IP [23]. Moreover, downregulation of GLT-1 pro-
tein expression induced by severe brain ischemia was prevented by IP [7,21].
Here, IP that was performed 3 days prior to 90-minute MCAO significantly lowered Glu
levels compared with those in rats subjected to ischemia alone in both the frontal cortex and
hippocampus during ischemia. Gong et al. [24] have also shown that IP significantly attenuates
increased Glu concentrations during global brain ischemia in rats. These changes were directly
associated with GLT-1 activity. Pre-administration of dihydrokainate, a GLT-1 inhibitor,
diminishes the protective effects of IP and sustains the elevated Glu levels during brain ische-
mia. Gong et al. [24] have also found that induction of tolerance to brain ischemia through IP
is associated with upregulation of GLT-1 expression. These findings are consistent with our
present report, which showed that the development of tolerance to brain ischemia induced by
IP is accompanied by attenuation of reduced GLT-1 expression that occurs after 90-minute
MCAO [7]. The immunofluorescence staining results showed strong coexpression of GLT-1
and GFAP in both the frontal cortex and CA1 field of the hippocampus. This finding suggests
that modulation of the GLT-1 levels in astrocytes is responsible for restoration of proper Glu
clearance in animals that underwent IP prior to brain ischemia. In addition, the staining
showed weaker coexpression of xCT and GFAP in animals that underwent IP, and this result
correlates with reduced Glu levels during prolonged ischemia.
The second preconditioning strategy used in this study was administration of 3NP—an irre-
versible inhibitor of succinate dehydrogenase activity, an enzyme involved in the mitochon-
drial respiratory chain [25]. 3NP has been shown to activate NF-κB, a transcription factor [26]
that promotes GLT-1 expression [27]. The Glu level following administration of 3NP has not
been investigated in the MCAO animal model. In the present study, administration of 3NP
prior to 90-minute brain ischemia significantly reduced Glu levels in samples collected during
MCAO in the frontal cortex and hippocampus. Moreover, in the hippocampus, decreased Glu
levels were also found during the preischemic period as well as during the initial phase of
reperfusion. These results may also be associated with increased GLT-1 protein levels in ani-
mals pretreated with 3NP. Previously, we found that this preconditioning strategy attenuated
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decreased GLT-1 protein expression in severe brain ischemia in a similar manner to IP [7].
Moreover, brain sections from animals that received 3NP prior to severe ischemia showed
stronger expression of GLT-1 on astrocytes in the frontal cortex and CA1 field of the hippo-
campus comparing with that in non-preconditioned animals. Similar to IP rats, 3NP pretreat-
ment also reduced the expression of xCT on astrocytes in both examined brain structures.
In reference to these recognized preconditioning strategies, we studied the effects of CEF
and NAC as potential inducers of brain tolerance to ischemia. Ceftriaxone, a beta-lactam anti-
biotic, is known to induce GLT-1 expression. The neuroprotective effects of CEF have been
shown in vitro [9]. Moreover, CEF has demonstrated neuroprotective activity in several
ischemia models, including focal cerebral ischemia induced by MCAO and global ischemia
[7,10,28–31]. These effects of CEF have been linked to GLT-1 upregulation [10,30,31]. In the
current study, we showed that these protective effects of CEF administration were associated
with significantly lower Glu levels in aCSF samples collected during ischemia in both the fron-
tal cortex and hippocampus. Moreover, we have previously demonstrated that CEF adminis-
tration inhibits GLT-1 protein downregulation caused by severe ischemia [7]. These findings
are consistent with our immunofluorescence staining. Specifically, we observed stronger GLT-
1 expression on astrocytes in both the frontal cortex and CA1 field of the hippocampus. All
these changes are comparable to the effects obtained by IP with 3NP used as the precondition-
ing strategy. The immunofluorescence results also indicate reduced expression of xCT on
astrocytes in both the frontal cortex and CA1 field of the hippocampus of animals pretreated
with CEF prior to ischemia. This finding may suggest that decreased xCT expression is associ-
ated with reduced extracellular Glu levels during MCAO.
It is worth to mention, that the most current data indicate that CEF may not only increase
GLT-1, but also xCT expression. Knackstedt and co-workers (2010) showed, that CEF attenua-
tion of reinstatement in rats, trained to self-administer cocaine, involves upregulation of both
GLT-1 and xCT protein expression in nucleus accumbens [32]. It was suggested, that this xCT
up-regulation, may lead to an increased non-synaptic glutamate efflux via xc- system. This in
turn may stimulate extrasynaptic mGluR2/3 and in consequence reduce synaptic glutamate
release [33]. Employing antisense strategy to knock-down GLT-1 expression in ceftriaxone
inhibition of reinstatement in cocaine addiction, prevented from upregulation of xCT. Simi-
larly, xCT knockdown prevented from GLT-1 expression up-regulation in the same model.
This intriguing phenomenon shows a common regulatory mechanism for GLT-1 and xCT
expression. It has been claimed, that at least in that experimental design the action of ceftriax-
one, leading to up-regulation of both GLT-1 and xCT transporters expression does not involve
transcriptional mechanism [34]. Also, up-regulation of xCT expression at the mRNA level as
well as an increase in xc- activity was found in HT22 cells pre-treated with CEF for 7 days
before exposure to toxic concentration of glutamate. These cells also showed higher expression
of nuclear factor erythroid 2-related factor 2 (Nrf2) at the protein level, which activates tran-
scription of xCT gene. Thus, this increase in Nrf2 protein level, is the probable mechanism of
CEF-stimulated xCT expression up-regulation in this in vitro model [35].
The second pharmacological attempt to induce brain tolerance to ischemia was 5-day
administration of NAC. Similar to CEF, treatment with NAC significantly lowered the level of
Glu in aCSF obtained during brain ischemia in the frontal cortex and hippocampus. NAC is a
glutathione synthesis substrate and thus promotes free radical species scavenging and cell sur-
vival. Thus, the simplest explanation for the reduced Glu levels in animals that were exposed to
NAC before ischemia could be the reduction of oxidative stress-induced damage that pro-
motes excitotoxicity [36]. Although NAC has been shown to upregulate expression of GLT-1
[37], it seems unlikely that the above changes are associated with modulation of this Glu trans-
porter. Immunofluorescence GLT-1 staining in both the frontal cortex and hippocampus of
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animals pretreated with NAC did not differ from the results seen in animals that underwent
90-minute MCAO alone. Additionally, in our previous study, administration of NAC did not
change GLT-1 mRNA and protein expression after brain ischemia [7]. On the other hand, we
cannot exclude the possibility that the observed decrease in Glu levels after NAC administra-
tion in animals that underwent brain ischemia may be due to modulation of system xc
- expres-
sion. Previously, we have found a significant reduction in xCT protein expression following
administration of NAC in animals that underwent 90-minute MCAO, as well as in control rats
(see S15 Fig) [7]. The immunofluorescence staining in this study showed that xCT expression
on astrocytes could be reduced in the analyzed brain regions. However, the xCT expression in
neuronal cells seemed to be stronger in animals pretreated with NAC. This finding could sug-
gest different regulation of xCT expression depending on the cell type. Under conditions with
compromised Glu uptake (like ischemia), increased Il-1β has been shown to enhance the
expression/activity of system xc
- only on astrocytes, which contributes to increased excitotoxi-
city [38]. Preconditioning strategies, such as IP and 3NP, are known to reduce Il-1β expres-
sion, and this may explain the obtained results for xCT and GFAP coexpression [39]. There
are also data confirming similar influences of NAC on the expression of Il-1β [12]. Thus, one
can speculate that the interventions used in this study caused changes in the expression of xCT
but only within astrocytes. However, we did not perform quantitative analysis of the immuno-
fluorescence staining of transporter expression.
In conclusion, the results of the current study showed the protective effects of two pharma-
cological strategies, namely, CEF and NAC, which were demonstrated by reduction of Glu lev-
els during severe brain ischemia, resembling the effects of the two reference preconditioning
methods, IP and 3NP. Changes in the expression levels of xCT and GLT-1 are cell-type specific
and mirror the neuroprotective properties of the studied compounds.
Supporting information
S1 Fig. Expression of GLT-1 on astrocytes within motor-frontal cortex of sham animals.
GLT-1 (Texas Red, red) and GFAP (FITC, green) double staining of brain sections of animals
subjected to sham surgery, preceded by preconditioning. Scale bars represent 25 μm, for each
group n = 8.
(TIF)
S2 Fig. Expression of GLT-1 on astrocytes within CA1 field of hippocampus of sham ani-
mals. GLT-1 (Texas Red, red) and GFAP (FITC, green) double staining of brain sections of
animals subjected to sham surgery, preceded by preconditioning. Scale bars represent 25 μm,
for each group n = 8.
(TIF)
S3 Fig. Expression of xCT on astrocytes within motor-frontal cortex of animals subjected
to brain ischemia. xCT (Texas Red, red) and GFAP (FITC, green) double staining of brain
sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale bars
represent 10 μm, for each group n = 8.
(TIF)
S4 Fig. Expression of xCT on astrocytes within motor-frontal cortex of sham animals. xCT
(Texas Red, red) and GFAP (FITC, green) double staining of brain sections of animals sub-
jected to sham surgery, preceded by preconditioning. Scale bars represent 10 μm, for each
group n = 8.
(TIF)
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S5 Fig. Expression of xCT on astrocytes within CA1 field of hippocampus of animals sub-
jected to brain ischemia. xCT (Texas Red, red) and GFAP (FITC, green) double staining of
brain sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale
bars represent 10 μm, for each group n = 8.
(TIF)
S6 Fig. Expression of xCT on astrocytes within CA1 field of hippocampus of sham animals.
xCT- (Texas Red, red) and GFAP (FITC, green) double staining of brain sections of animals
subjected to sham surgery, preceded by preconditioning. Scale bars represent 10 μm, for each
group n = 8.
(TIF)
S7 Fig. Expression of xCT on neuronal cells within motor-frontal cortex of sham animals.
xCT (Texas Red, red) and MAP2 (Alexa Fluor 488, green) double staining of brain sections of
animals subjected to sham surgery, preceded by preconditioning. Scale bars represent 25 μm,
for each group n = 8.
(TIF)
S8 Fig. Expression of xCT on neuronal cells within CA1 field of hippocampus of sham ani-
mals. xCT (Texas Red, red) and MAP2 (Alexa Fluor 488, green) double staining of brain sec-
tions of animals subjected to sham surgery, preceded by preconditioning. Scale bars represent
25 μm, for each group n = 8.
(TIF)
S9 Fig. Expression of xCT on microglia within motor-frontal cortex of animals subjected
to brain ischemia. xCT (Texas Red, red) and Iba1 (FITC, green) double staining of brain sec-
tions of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale bars rep-
resent 10 μm, for each group n = 8.
(TIF)
S10 Fig. Expression of xCT on microglia within motor-frontal cortex of sham animals.
xCT (Texas Red, red) and Iba1 (FITC, green) double staining of brain sections of animals sub-
jected to sham surgery, preceded by preconditioning. Scale bars represent 10 μm, for each
group n = 8.
(TIF)
S11 Fig. Expression of CT on microglia within CA1 field of hippocampus of animals sub-
jected to brain ischemia. xCT (Texas Red, red) and Iba1 (FITC, green) double staining of
brain sections of animals subjected to 90-minute MCAO, preceded by preconditioning. Scale
bars represent 10 μm, for each group n = 8.
(TIF)
S12 Fig. Expression of xCT on microglia within CA1 field of hippocampus of sham ani-
mals. xCT (Texas Red, red) and Iba1 (FITC, green) double staining of brain sections of ani-
mals subjected to sham surgery, preceded by preconditioning. Scale bars represent 10 μm, for
each group n = 8.
(TIF)
S13 Fig. Neuroprotective effects of used interventions. (A) decreased neurological deficit 24
h after ischemia (p<0.001 vs. ISCH, Mann-Whitney, n = 24/group). (B) representative
TTC-stained brain sections and corresponding histogram (C) representing calculated
infarct volume in VEH+ISCH, CEF+ISCH, NAC+ISCH, 3NP+ISCH, and IP+ISCH groups
(p<0.001 vs. VEH+ISCH, t-test, n = 8/group) 24 h after reperfusion. The figure obtained
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from our previous manuscript entitled: ‘N-Acetylcysteine and Ceftriaxone as Preconditioning
Strategies in Focal Brain Ischemia: Influence on Glutamate Transporters Expression’, Neuro-
toxicity Research, 2016; 29:539–550 under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/).
(TIF)
S14 Fig. Influence of used interventions on expression of mRNA (A) and protein (B) of
GLT-1 in frontal cortex (FC), hippocampus (HIP) and dorsal striatum (DS) in studied
groups: VEH+SHAM, VEH+ISCH, CEF+SHAM, CEF+ISCH, NAC+SHAM, NAC+ISCH,
3NP+SHAM, 3NP+ISCH, IP+ISCH, and IP+SHAM (p<0.05, p<0.01, p<0.001 vs
VEH+ISCH or VEH+SHAM, Student’s t-test, #p<0.05, ##p<0.01, ###p<0.001 vs VEH
+ISCH or VEH+SHAM, Two-way ANOVA, Post-hoc Tukey’s test, n = 8/group) 24 h after
reperfusion. The figure obtained from our previous manuscript entitled: ‘N-Acetylcysteine
and Ceftriaxone as Preconditioning Strategies in Focal Brain Ischemia: Influence on Gluta-
mate Transporters Expression’, Neurotoxicity Research, 2016; 29:539–550 under the terms of
the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/).
(TIF)
S15 Fig. Influence of used interventions on expression of mRNA (A) and protein (B) of xc-
in frontal cortex (FC), hippocampus (HIP) and dorsal striatum (DS) in studied groups:
VEH+SHAM, VEH+ISCH, CEF+SHAM, CEF+ISCH, NAC+SHAM, NAC+ISCH, 3NP
+SHAM, 3NP+ISCH, IP+ISCH, and IP+SHAM (p<0.05, p<0.01, p<0.001 vs VEH
+ISCH or VEH+SHAM, Student’s t-test, #p<0.05, ##p<0.01, ###p<0.001 vs VEH+ISCH or
VEH+SHAM, Two-way ANOVA, Post-hoc Tukey’s test, n = 8/group) 24 h after reperfusion.
The figure obtained from our previous manuscript entitled: ‘N-Acetylcysteine and Ceftriaxone
as Preconditioning Strategies in Focal Brain Ischemia: Influence on Glutamate Transporters
Expression’, Neurotoxicity Research, 2016; 29:539–550 under the terms of the Creative Com-
mons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
(TIF)
S16 Fig. Confirmation of the specificity of primary antibody against xCT and the role of
antigen retrieval for the proper antibody binding. 1 & 2: double immunofluorescent staining
with or without antigen retrieval. 3 & 4: negative staining control with the omission in the pro-
cedure adding of primary antibody against xCT, MAP2 or both antibodies. 5A: An exemplary
immunoblot membrane obtained using the same antibody anti-xCT as in immunofluorescent
staining. 5B: A positive control staining of brain meninges, where expression of system xc
- is
known to be high.
(TIF)
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